ArticleJournal of inflammation research2026
Identification and Analysis of Remimazolam's Potential Therapeutic Mechanisms in Murine Sepsis-Associated Encephalopathy via Transcriptomic Analysis.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sepsis-associated encephalopathy (SAE) is a common complication of sepsis, marked by neuroinflammation and cognitive impairment. Remimazolam (Rem), a novel ultra-short-acting benzodiazepine, exhibits potential anti-inflammatory and neuroprotective effects; however, its molecular mechanisms in SAE remain poorly understood. Methods: Male mice were randomly assigned to three groups: SHAM (Con, n=6), Sepsis (CLP, n=6), and remimazolam-treated Sepsis (Rem, n=6). Hippocampal tissues were collected for RNA sequencing. Differential expression analysis was performed to identify genes modulated by Rem treatment. To further screen candidate genes, weighted gene co-expression network analysis (WGCNA) and protein-protein interaction (PPI) networks were utilized, and functional enrichment was assessed through gene set enrichment analysis (GSEA). Immune microenvironment alterations were compared across groups, and potential therapeutic compounds targeting hub genes were predicted using public drug-gene interaction databases. Hub gene expression was validated at both mRNA (qRT-PCR) and protein levels. Results: RNA-seq identified 3397 and 914 differentially expressed genes (DEGs) in the Sepsis (CLP vs Con) and remimazolam-treated (Rem vs CLP) groups, respectively. A total of 647 key DEGs with opposing expression trends were screened. Through WGCNA and PPI analysis, five hub genes-ICAM1, Tlr2, Cd274, FOS, and SOCS3-were identified. Pathways related to inflammatory response, IL6/JAK/STAT3 signaling, and TNFα/NF-κB signaling were significantly enriched with these genes, suggesting their potential role in the pathogenesis of SAE. Among the twenty-one candidate drugs predicted to target these hub genes, AVELUMAB-CD274 and LIFITEGRAST-ICAM1 exhibited high binding affinity. The expressions of ICAM1, Tlr2, Cd274, and SOCS3 were further validated at both mRNA (qRT-PCR) and protein levels, corroborating the transcriptomic findings. Conclusion: This study reveals that ICAM1, Tlr2, Cd274, and SOCS3 are key molecular correlates of remimazolam treatment in a murine SAE model. Our transcriptomic analysis offers insights into the molecular basis of remimazolam's protective effects, highlighting these genes and pathways for future research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.